Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$2.77 – $2.85
Volume14,063
Market cap$26M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for EVAX.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for EVAX.
Recent news
Company coverage with links to the original publishers.
Evaxion A/S announced its 2027 financial calendar with quarterly business updates and earnings releases scheduled throughout the year, starting with full year 2026 results on March 4, 2027. The company also filed an amendment to its registration statement related to a 2025 EIB debt settlement agreement. Additionally, new Phase 2 data for personalized cancer vaccine EVX-01 demonstrated strong neoantigen-specific T cell responses, validating the company's AI-Immunology platform.
Evaxion A/S filed an amendment to its F-1 registration statement related to a July 2025 debt settlement agreement with the European Investment Bank (EIB). Under the agreement, EIB converted €3.5 million of debt into warrants for 38.45 million shares at $4.87 per ADS. The conversion provided Evaxion with immediate €3.5 million equity increase and potential additional proceeds of approximately $1.5 million from warrant exercises, strengthening the company's capital structure and financial flexibility.
Evaxion announced new phase 2 biomarker data for its personalized cancer vaccine EVX-01 in advanced melanoma patients, demonstrating potent neoantigen-specific T-cell responses and validating the predictive performance of its AI-Immunology™ platform. The data showed 89% vaccine target precision with sustained clinical responses at three-year follow-up, including a 75% objective response rate at two years.
Evaxion A/S, a clinical-stage TechBio company, has won the 2026 International Prix Galien Award for its AI-Immunology platform as the best digital health solution, marking the first time a Danish company has received this prestigious award. The recognition follows positive three-year phase 2 trial data for its personalized cancer vaccine EVX-01 in advanced melanoma patients, which demonstrated 89% vaccine target precision and sustained T-cell responses.
Evaxion will present new immune profiling data from its phase 2 trial of personalized cancer vaccine EVX-01 combined with pembrolizumab at the SITC 2026 Annual Meeting in November. The data will showcase systemic immunomodulatory effects beyond vaccine-specific T-cell responses. Previous two-year data showed a 75% objective response rate in advanced melanoma patients, with 92% still responding at two-year follow-up and no relapses observed.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.